Agenus tries again with the FDA
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
Randomised data will be needed to answer lingering questions about DKN-01.
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.